Commentary: Why the US FDA is taking a wait-and-see attitude on booster shots for US public

ATLANTA, Georgia: The key scientific advisory council of the US Food and Drug Administration (FDA) has voted to deny use of a booster shot of Pfizer’s mRNA vaccine to the general public – a move that will likely disappoint some public health experts pushing for a third dose to help slow the spread of COVID-19.

In a 16-2 vote on Friday (Sep 17), an independent committee of physicians, scientists and public health experts recommended against full use of the third dose of the vaccine, which now goes by the brand name Comirnaty.

However, the panel did recommend the shot for Americans aged 65 and older or those at high risk for severe COVID-19.

In recommending against the shot for the general public, the committee cited reasons such as lack of sufficient safety data in younger age groups as well as indications that the initial doses still seem to be providing robust protection against severe illness leading to hospitalisation and death.

The panel also agreed in a poll – but not a formal vote – that boosters would be beneficial for certain populations, such as healthcare workers and others at high risk for occupational exposure.

Although the vote is not binding, it is likely that it will form the basis of a formal FDA recommendation.

The push for a booster was predictable, although the outcome of the vote was always far from certain. Over the past year, significant research and public reporting have focused on the durability of the immune response following the first and second doses of the COVID-19 mRNA vaccines.

This work has been critical to scientists’ understanding of how long the immune responses from vaccination can provide protection, and whether that protection extends to new and emerging variants of the SARS-CoV-2 virus.

WANING ANTIBODIES

The good news is that the mRNA vaccines do appear to provide continued efficacy against serious illness or death caused by new strains of the coronavirus, including the highly infectious Delta variant.

But data on the longevity of this protection has been more mixed and is still limited in scope.

Although there are indications that immune “memory” is being established in vaccine recipients – almost certainly providing partial protection in the long term – the antibodies responsible for stopping the virus in its tracks before infection occurs appear to wane over the course of months following the second dose.

This is not surprising to immunologists and does not mean the vaccine isn’t working. Antibodies wane as a normal course of an immune response to any vaccine.

This is why you need a tetanus booster every decade or so, and why the measles, mumps and rubella vaccine is administered in three doses – not just two.

The question is simply how fast antibodies decline, and at what point they no longer provide adequate protection. At that point, an additional dose of the vaccine is recommended to boost the antibody numbers back up to protective levels.

In this case, widespread reporting of breakthrough infections – infections in individuals who have been fully vaccinated – and research citing the possibility of declining immunity in populations vaccinated early in the pandemic brought discussions of the need for boosters quickly to the forefront.

SEPARATING POLITICS FROM DATA

Against this backdrop of mixed data, the FDA panel had to weigh the risks and benefits surrounding booster shots.

While the third dose of vaccine would have been identical to those already fully approved – and as such deemed safe – they would not be without side effects similar to those seen in the first and second doses.

In addition, serious conditions such as myocarditis – an inflammation of the heart – that have been recorded in rare and isolated cases after the initial vaccine shots will likely occur following the booster as well.

This, in addition to a debate around the absolute benefit of a third shot to maintain current protection levels in otherwise healthy vaccinated individuals, has led many public health officials to express concern that the review is premature and risks further confusing and alienating an already divided American public.

With the Biden administration having already publicly backed a third dose for all vaccinated Americans in August, the committee was tasked with separating the politics from the data to weigh in on whether the benefits of a booster shot outweighed the risks to an already-hesitant American public.

In rejecting the proposal, the FDA panel has signalled its confidence in the original vaccination course among healthy individuals, and will wait for additional data before identifying waning antibody levels as a significant threat to public safety.

However, its support for boosting those at high risk for exposure to COVID-19 suggests a recognition that additional shots may yet be necessary to fully protect the public at large.

Matthew Woodruff is Instructor of Human Immunology at Emory University. This commentary first appeared on The Conversation.